Viral vectors and plasmid DNA play critical roles in biotechnology and gene therapies, acting as carriers for therapeutic genes and facilitating research and biopharmaceutical production. Their utilization significantly advances medical treatments and deepens our comprehension of genetic mechanisms.
BOSTON, April 17, 2024 /PRNewswire/ — “According to the latest BCC Research study, the demand for Viral Vector and Plasmid DNA: Technologies and Global Markets is growing from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.”
The report gives a thorough look at the viral vector and plasmid DNA technologies market, especially in cell and gene therapies. It covers key players, their products, and recent activities. By highlighting trends and challenges, it helps businesses make smart decisions about what to produce and license. The report also breaks down the market by product type, applications, and where products are used. It’s useful for companies, distributors, and exporters to understand market trends at both segment and country levels.
Gene therapy, a cutting-edge medical technology, now uses our genes to treat diseases. Once considered science fiction, it’s now a reality, offering hope to patients with conditions like cancer and rare diseases. This technology could revolutionize healthcare, especially if successful in treating infectious diseases like HIV and common conditions like diabetes. The key technology behind gene therapy involves using viral vectors and plasmid DNA to insert therapeutic genes. The report on Viral Vector and Plasmid DNA is aimed at various groups, including pharmaceutical companies, healthcare professionals, researchers, patients, and anyone interested in learning about these advancements in medicine.
To gain further insight into the report Viral Vector and Plasmid DNA: Technologies and Global Markets, click here for more information.
Driving Factors
Surge in Viral Vectors and Plasmid DNA Production: Scientists and companies are producing more viral vectors and plasmid DNA than ever before. These tools are crucial for gene therapy, vaccines, and other medical treatments. To understand, think of a factory churning out lots of tiny delivery trucks (viral vectors) and instruction manuals (plasmid DNA) to fix genetic problems in our bodies.
Rising Prevalent Cases of Cancer: More people are being diagnosed with cancer, and treatments often utilize viral vectors and plasmid DNA to target cancer cells specifically. Imagine these tools as special agents sneaking into cancer cells and delivering a message to stop them from growing.
Increasing Investments in Cell and Gene Therapy Development: Companies and researchers are investing more money in finding new ways to treat diseases using cells and genes. Viral vectors and plasmid DNA play a crucial role in these therapies. Picture scientists in labs, striving to create better tools to fix our bodies at the genetic level.
Approvals and Clinical Trials of Vector-Associated Cell and Gene Therapy: Regulatory agencies are approving the use of these therapies in patients, indicating that they are becoming safer and more effective. Picture doctors conducting trials on real patients, akin to a trial run before a big race.
Request a Sample Copy of the Viral Vector and Plasmid DNA: Technologies and Global Markets Report.
Report Synopsis
|
Report Metrics |
Details |
|
Base year considered |
2022 |
|
Forecast Period considered |
2023-2028 |
|
Base year market size |
$2.4 billion |
|
Market Size Forecast |
$7.1 billion |
|
Growth Rate |
CAGR of 19.7% from 2023 to 2028 |
|
Segment Covered |
By Product Type, Application, End User, and Region |
|
Regions covered |
North America, Europe, Asia-Pacific, Latin America, and the Rest of the World (RoW) |
|
Key Market Drivers |
|
Segmentation Analysis
- By Product Type Analysis
Viral vectors are like tiny delivery vehicles, carrying genetic material to fix or modify genes in cells. Plasmid DNA, on the other hand, is manipulated in labs to create custom genetic instructions. Together, they help develop treatments for diseases.
- By Application Analysis
In medicine, different areas use genetic tools differently. For cancer, these tools target cancer cells. Genetic disorders are treated by fixing or replacing faulty genes. Infectious diseases are fought by boosting the body’s defenses or attacking the germs directly. Cardiovascular diseases benefit from treatments that improve heart function or repair damaged tissue.
This report on the Viral Vector and Plasmid DNA Technologies and Global Markets provides comprehensive insights and analysis, addressing the following key questions:
1. What is the projected market size and growth rate of the viral vector and plasmid DNA technologies global market?
The global viral vector and plasmid DNA market is projected to grow from $2.4 billion in 2022 to $7.1 billion in 2028 at a compound annual growth rate (CAGR) of 19.7% during the forecast period.
2. What are the key factors driving the growth of the viral vector and plasmid DNA technologies market?
The viral vector and plasmid DNA technologies market is driven by the increasing adoption of viral vector associated cell and gene therapies for cancer and rare genetic disorders. Contract development manufacturers and biopharmaceutical companies increasing the scale of production to meet the surge for viral vectors and plasmid DNA due to accelerated FDA approvals of cell and gene therapies are the key factors driving the market growth.
3. What segments are covered in the viral vector and plasmid DNA technologies market?
The viral vector and plasmid DNA technologies market is segmented based on the product type, by application and by geographic region.
4. By Type, which segment will dominate the market by the end of 2028?
The viral vector segment will dominate the market by the end of 2028.
5. Which region has the highest market share in the Viral Vector and Plasmid DNA market?
North America holds the highest share in the market.
Some of the Key Market Players Are:
- AGILENT TECHNOLOGIES INC.
- BLUEBIRD BIO INC.
- CATALENT INC.
- DANAHER CORP.
- FUJIFILM HOLDINGS CORP.
- GENSCRIPT
- GILEAD SCIENCES INC.
- LONZA
- NOVARTIS AG
- OXFORD BIOMEDICA PLC
- PLASMIDFACTORY GMBH
- REGENXBIO INC.
- THERMO FISHER SCIENTIFIC INC.
- VGXI INC.
Browse More Related Reports:
Global Cell and Gene Therapy Market: This report explores into the cell and gene therapy market, examining therapy types, products, applications, and regions. BCC Research predicts growth over five years, identifies key drivers and challenges, and provides market shares for major players. With forecasts to 2028, the report also discusses emerging technologies and trends, along with insights into environmental, social, and governance (ESG) development and investment outlooks.
mRNA: Therapeutics and Global Markets: This report explores into mRNA therapeutics, exploring different mRNA types used in therapy. It looks at patents, clinical trials, and market trends up to 2028. The study also profiles key players and splits the market by region. BCC Research summarizes industry acquisitions and alliances from January 2020 to December 2022, showing trends in this area.
Directly Purchase a copy of the report with BCC Research.
For further information or to make a purchase, please get in touch with [email protected].
About BCC Research
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
Email: [email protected],
Phone: +1 781-489-7301
For media inquiries, email [email protected] or visit our media page for access to our market research library.
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
SOURCE BCC Research LLC
